| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5545 | 2021 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 2445* | 2021 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1389 | 2021 |
| SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 959 | 2022 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 786 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 760 | 2021 |
| Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1 TK Berthoud, M Hamill, PJ Lillie, L Hwenda, KA Collins, KJ Ewer, A Milicic, ... Clinical infectious diseases 52 (1), 1-7, 2011 | 355 | 2011 |
| Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre … CD Russell, CJ Fairfield, TM Drake, L Turtle, RA Seaton, DG Wootton, ... The Lancet Microbe 2 (8), e354-e365, 2021 | 322 | 2021 |
| Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised … NJ Brendish, AK Malachira, L Armstrong, R Houghton, S Aitken, ... The Lancet Respiratory Medicine 5 (5), 401-411, 2017 | 311 | 2017 |
| Preliminary assessment of the efficacy of a t-cell–based influenza vaccine, MVA-NP+ M1, in humans PJ Lillie, TK Berthoud, TJ Powell, T Lambe, C Mullarkey, AJ Spencer, ... Clinical infectious diseases 55 (1), 19-25, 2012 | 296 | 2012 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 282 | 2021 |
| Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective ALN Chapman, S Dixon, D Andrews, PJ Lillie, R Bazaz, JD Patchett Journal of antimicrobial chemotherapy 64 (6), 1316-1324, 2009 | 280 | 2009 |
| ChAd63-MVA–vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans SH Sheehy, CJA Duncan, SC Elias, P Choudhary, S Biswas, FD Halstead, ... Molecular Therapy 20 (12), 2355-2368, 2012 | 254 | 2012 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 399 (10320), 143, 2022 | 252 | 2022 |
| Novel coronavirus disease (Covid-19): the first two patients in the UK with person to person transmission PJ Lillie, A Samson, A Li, K Adams, R Capstick, GD Barlow, N Easom, ... Journal of Infection 80 (5), 578-606, 2020 | 245 | 2020 |
| Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study RK Gupta, EM Harrison, A Ho, AB Docherty, SR Knight, M van Smeden, ... The Lancet Respiratory Medicine 9 (4), 349-359, 2021 | 231 | 2021 |
| Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a … ASV Stuart, RH Shaw, X Liu, M Greenland, PK Aley, NJ Andrews, ... The Lancet 399 (10319), 36-49, 2022 | 227 | 2022 |
| Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the … CI Bloom, TM Drake, AB Docherty, BJ Lipworth, SL Johnston, ... The Lancet Respiratory Medicine 9 (7), 699-711, 2021 | 178 | 2021 |
| A prenylated dsRNA sensor protects against severe COVID-19 A Wickenhagen, E Sugrue, S Lytras, S Kuchi, M Noerenberg, ML Turnbull, ... Science 374 (6567), eabj3624, 2021 | 161 | 2021 |
| Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study TM Drake, AM Riad, CJ Fairfield, C Egan, SR Knight, R Pius, ... The Lancet 398 (10296), 223-237, 2021 | 158 | 2021 |
Gavin BarlowProfessor of Infection, Hull York Medical School, University of York. Hon. Consultant在 york.ac.uk 的电子邮件经过验证
